Teone Church

Teon Therapeutics Announces Clinical Trial Collaboration With Merck to Evaluate TT-816, a Novel Oral Immune Response Modifier, in Combination with KEYTRUDA® (pembrolizumab)

Retrieved on: 
Wednesday, January 18, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, MSD, CB2, IO, Teone Church, Cancer, Immunity, Therapy, Neoplasm, Immunotherapy, Trial of the century, FRCPC, FACP, Hope, NK, Patient, Merck Sharp & Dohme Federal Credit Union, GPCR, PD-1, Merck & Co., Pembrolizumab, Pharmaceutical industry, Merck

The agreement is for the combination arm of Teon’s ongoing, two-armed, open-label, dose escalation and expansion clinical study and will evaluate Teon’s oral, immune response modifier, TT-816, in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), for patients with advanced solid tumors.

Key Points: 
  • The agreement is for the combination arm of Teon’s ongoing, two-armed, open-label, dose escalation and expansion clinical study and will evaluate Teon’s oral, immune response modifier, TT-816, in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), for patients with advanced solid tumors.
  • The study will include patients with many difficult-to-treat cancers with high unmet medical need who have not responded to the standard-of-care and may have limited treatment options.
  • “We are fortunate to have the opportunity to collaborate with Merck for this Phase 1/2 trial.
  • KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Teon Therapeutics Announces First Patient Treated in Phase 1/2 Clinical Trial of TT-816, a Novel Oral Immune Checkpoint Inhibitor, in Patients with Advanced Solid Tumors

Retrieved on: 
Tuesday, November 1, 2022
Research, Venture Capital, Clinical Trials, Professional Services, Biotechnology, Health, Pharmaceutical, Science, Oncology, CB2, Ovarian cancer, CB1, CEO, GPCR, Inflammation, RCC, PD-1, Immunity, Lung, FIH, Clinical trial, FRCPC, Cancer, Brain, Renal cell carcinoma, Immunotherapy, Ovary, Immune system, Research, Safety, Hope, Company, Therapy, FACP, Pharmacokinetics, Patient, NK, NSCLC, Phase 1, Pharmaceutical industry, Vaccine, Teone Church

The study will include patients with advanced solid tumors with high unmet medical need who have not responded to the standard-of-care and may have no more treatment options.

Key Points: 
  • The study will include patients with advanced solid tumors with high unmet medical need who have not responded to the standard-of-care and may have no more treatment options.
  • As a novel checkpoint inhibitor with unique mechanisms of action, I am hopeful about the role of TT-816 in the treatment landscape.
  • The Phase 1/2 clinical trial is actively recruiting patients with advanced solid tumors in several sites.
  • Teon has an ongoing Phase 1/2 trial evaluating TT-816, a cannabinoid CB2 antagonist and a Phase1/2 trial evaluating TT-702, an A2B receptor-specific antagonist.

Teon Therapeutics Announces FDA Acceptance of IND Application for Novel, Oral Immune Checkpoint Inhibitor, TT-816

Retrieved on: 
Wednesday, June 1, 2022
Research, Women, FDA, Clinical Trials, Biotechnology, Consumer, Health, Science, Oncology, Other Science, Aggression, Colorectal cancer, Cancer Medicine, Journal, Lung, Cancer, Survival, Doctor of Philosophy, Food, NK, G protein-coupled receptor, GPCR, Breast cancer, Cannabinoid, Inflammation, Large-cell lung carcinoma, IND, HER2, Therapy, FDA, Patient, Tumor microenvironment, Review, Initiation, Immune system, Research, MD, Clinical trial, Overalls, CB1, NSCLC, Immunology, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Neoplasm, Ovary, Safety, CB2, Pharmaceutical industry, Vaccine, Teone Church

TT-816 is a novel, oral cannabinoid CB2 receptor antagonist acting as an immune checkpoint inhibitor for the treatment of a broad range of solid tumors.

Key Points: 
  • TT-816 is a novel, oral cannabinoid CB2 receptor antagonist acting as an immune checkpoint inhibitor for the treatment of a broad range of solid tumors.
  • The FDAs acceptance of the IND for TT-816 is an important validation of our approach to targeting a novel immune checkpoint pathway and marks a significant milestone for Teon, said Serge Messerlian, Chief Executive Officer of Teon.
  • The cannabinoid CB2 receptor, selectively targeted by TT-816, is a peripheral receptor found predominantly in the immune system and regulates inflammation and the immune response.
  • TT-816 is a first-in-class, oral cannabinoid CB2 receptor antagonist acting as an immune checkpoint inhibitor and is highly selective for the CB2 receptor versus the CB1 receptor.

Teon Therapeutics Names Serge Messerlian as CEO

Retrieved on: 
Tuesday, March 8, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Baxalta, Serge, G protein-coupled receptor, A2B, GPCR, Patient, MBA, Cancer Research UK, Industry, Immunotherapy, Royal Marsden Hospital, MPH, Genetics, The Royal Marsden NHS Foundation Trust, University, Organization, Doctor of Philosophy, Safety, PD-1, Baxter International, FDA, Therapy, Biology, Drug development, Adenosine, Multimedia, Biotechnology, Human genetics, Cancer, Janssen Pharmaceuticals, Institute of Cancer Research, CEO, NHS foundation trust, McGill University, Neoplasm, CSO, Hematology, The Institute, Tumor microenvironment, Johnson & Johnson, Immune system, Degenerative disease, Management, Pharmaceutical industry, Physiology, Teone Church, Actelion, MD

Teon Therapeutics (Teon), a clinical-stage biopharmaceutical company targeting metabolic signaling pathways and pioneering the development of G-Protein Coupled Receptor (GPCR) immuno-oncology therapies in difficult-to-treat cancers, today announced the appointment of Serge Messerlian as Chief Executive Officer and member of the board of directors.

Key Points: 
  • Teon Therapeutics (Teon), a clinical-stage biopharmaceutical company targeting metabolic signaling pathways and pioneering the development of G-Protein Coupled Receptor (GPCR) immuno-oncology therapies in difficult-to-treat cancers, today announced the appointment of Serge Messerlian as Chief Executive Officer and member of the board of directors.
  • Mr. Messerlian will assume the role from co-founder, acting CEO and Chief Scientific Officer (CSO), Lina Yao, MD, PhD, who remains as CSO.
  • View the full release here: https://www.businesswire.com/news/home/20220308005412/en/
    Serge Messerlian, CEO of Teon Therapeutics (Photo: Business Wire)
    Mr. Messerlian brings to the role significant experience in the industry, across a range of roles and therapeutic areas including hematology, oncology, immunology, and rare diseases.
  • For more information about Teon Therapeutics, please visit: www.teontherapeutics.com .